GeneDx Faces Class Action Lawsuit Following 49% Stock Collapse

The legal action, filed by Levi & Korsinsky, LLP, alleges that GeneDx misled shareholders regarding the viability of its Fabric Genomics acquisition and the state of its core testing business. During the class period, shares reached a high of $167.52, buoyed by management’s optimistic growth claims. However, the company’s Q1 2026 earnings release revealed that those claims lacked a factual basis, leading to an immediate market correction that erased billions in shareholder value.

The corrective disclosures unveiled a series of systemic issues previously hidden from the public. Beyond the Fabric Genomics write-off, GeneDx reported that blended average reimbursement rates had plummeted to $3,300 from $3,800 just six months earlier. Furthermore, the company slashed its full-year revenue outlook by $65 million, while admitting that its Fabric technology was limited to international markets, contrary to earlier promises of broad application. Investors seeking to serve as lead plaintiff must file their claims by August 3, 2026.